TDF Combined With LDT for the Treatment of HBeAg-positive Hepatitis B Patients With Poor Response to TDF for 12 Months
Status:
Recruiting
Trial end date:
2022-12-30
Target enrollment:
Participant gender:
Summary
Studies have shown that the HBeAg seroconversion rate of HBeAg positive chronic hepatitis B
with tenofovir for one year's treatment was 17.8% and the negative conversion rate of their
HBeAg and HBV DNA were 20.0% and 97.6%. The HBeAg Seroconversion rate of these patients was
lower.Clinically, most patients need to take tenofovir for a long time, which may cause
serious complications such as renal function damage,with decreased therapy compliance and
Increased cost of treatment.In the course of tenofovir treatment, it is common that HBV-DNA
negative patients with HBeAg Being down poor or staying at a low positive level for a long
time keep taking the medicine. Therefore, it is Significant to Increase the HBeAg
seroconversion rate of tenofovir during the clinical treatment.
Telbivudine has a strong antiviral effect.Studies have shown that the HBeAg seroconversion
rate of HBeAg positive CHB for one year was 25%, which was higher than other nucleosides, and
it could also improve the damaged renal function to a certain extent.The HBeAg seroconversion
rate of patients with poor response to tenofovir for 12 months could be still poor if for 24
months . Therefore, this study is to observe the efficacy of these patients combined with
telbivudine.